A decade from now, 2020 likely will be considered a year like no other in terms of the massive amounts of capital raised amid a raging pandemic. Financing transactions of all types smashed records and in terms of volume hit 1,580, a total that was 42% higher than last year.

With several deals and M&As falling within the highest values on record, 2020 turned out to be a solid year for the biopharma industry. Expectations are optimistic moving into 2021, when the U.S. will welcome a new president and its citizens should reach herd immunity from COVID-19.

The attention the COVID-19 pandemic drew to the biopharma industry, the ease and convenience of virtual meetings, as well as massive amounts of available capital, all led to an extraordinary year for financings in 2020. The momentum appears to be continuing, particularly with venture capital rounds.

A decade from now, 2020 likely will be considered a year like no other in terms of the massive amounts of capital raised amid a raging pandemic. Financing transactions of all types smashed records and in terms of volume hit 1,580, a total that was 42% higher than last year despite the serious disruptions to normal business operations.

A quick look back at top stories.

Biopharma money raised to-date and by quarter in 2020, including public, private and other financings.